ArticleBMC infectious diseases2026
Clinical utility of the targeted next-generation sequencing for detection of Mycoplasma pneumoniae and antimicrobial resistance genes for adults.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMycoplasma pneumoniae pneumonia (MPP) is common in children, and its incidence among adolescents and adults has been increasing in recent years. Targeted next-generation sequencing (tNGS) is a rapid, accurate and comprehensive method for pathogen detection; however, few studies have investigated its application value in the diagnosis of MPP.
methodsNinety patients (aged over 14 years ) were enrolled in this study and divided into MPP group (31 cases) and non-Mycoplasma pneumoniae pneumonia (non-MPP) group (59 cases). Clinical data, thin-slice spiral computed tomography (CT) scans of the lungs, tNGS results from bronchoalveolar lavage fluid (BALF) and blood samples, as well as other routine biochemical and traditional respiratory pathogen detection results, were collected. Clinical manifestations, etiological findings, and the performance of tNGS detection were compared between adolescent and adult patients with MPP and non-MPP for clinical reference.
resultsCompared with the non-MPP group, adolescent and adult MPP patients exhibited distinct clinical features, including yellow sputum (35.5% vs. 88.1%, P = 0.03), headache (12.9% vs. 5.1%, P = 0.027), bronchial wall thickening (61.3% vs. 5.1%, P < 0.001), alveolar nodular exudative changes (51.6% vs. 3.9%, P < 0.001), and large airway sputum plugs (3.2% vs. 23.7%, P = 0.029). The sensitivity of tNGS in detecting Mycoplasma pneumoniae (M. pneumoniae) was 96.8%, which was superior to that of qPCR (80.6%) and IgM antibodies (67.7%). This technology can also simultaneously detect the coexistence of multiple pathogens with M. pneumoniae. Additionally, tNGS detected 10 antimicrobial resistance genes (ARGs) and 15 virulence factor genes in this study.
conclusionsThe imaging manifestations of MPP in adolescents and adults exhibit certain characteristics. Early recognition and timely diagnosis are the key to accurate diagnosis and improve prognosis. TNGS has superior diagnostic accuracy and provides essential data on resistance, its potential as a supplementary tool to assist in the quick detection of M. pneumoniae in adults remains promising. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.